₹365, up 0.48% from its previous close, while the benchmark index, Sensex, gained 0.30% to 35949.88.The drug maker announced that its plasmid DNA vaccine candidate for covid-19 (ZyCoV-D), developed indigenously at its Vaccine Technology Centre in Ahmedabad (Gujarat), has successfully completed the pre-clinical phase.
It has now received permission from the Central Drugs Standard Control Organisation (CDSCO), headed by the DCGI, to initiate Phase I/II human clinical trials in India.In animal studies, the vaccine was found to elicit a strong immune response in multiple animal species such as mice, rats, guinea pigs and rabbits.